Role of sulfiredoxin in systemic diseases influenced by oxidative stress

Redox Biology

Volumn 2, Issue , 2014, Pages 1023-1028

  Ramesh, Asha ^a   Varghese, Sheeja S ^a   Doraiswamy, Jayakumar ^a   Malaiappan, Sankari ^a  

^a SAVEETHA UNIVERSITY   (India)

Author keywords

Antioxidant; Oxidative stress; Reactive oxygen species; Sulfiredoxin; Systemic diseases

Indexed keywords

OXIDOREDUCTASE; REACTIVE OXYGEN METABOLITE; SULFIREDOXIN; THIOL; UNCLASSIFIED DRUG; SRXN1 PROTEIN, HUMAN; TUMOR PROTEIN;

ATHEROSCLEROSIS; CANCER CELL; CARCINOMA; CELL FUNCTION; CELL SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; HOMEOSTASIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SYSTEMIC DISEASE; ANIMAL; GENETICS; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; CARCINOMA; HUMANS; NEOPLASM PROTEINS; OXIDATIVE STRESS; OXIDOREDUCTASES ACTING ON SULFUR GROUP DONORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84908327087     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.09.002     Document Type: Review

References (49)

1. Sun Y., Hegamyer G., Colburn N.H. Molecular cloning of five messenger RNAs differentially expressed in preneoplastic or neoplastic JB6 mouse epidermal cells: one is homologous to human tissue inhibitor of metalloproteinases-3. Cancer Research 1994, 54:1139-1144. http://www.ncbi.nlm.nih.gov/pubmed/8118794.
2. Rhee S.G., Jeong W., Chang T.S., Woo H.A. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney International: Supplement 2007, 72:S3-S8. http://www.ncbi.nlm.nih.gov/pubmed/17653208, 10.1038/sj.ki.5002380.
3. Noh Y.H., Baek J.Y., Jeong W., Rhee S.G., Chang T.S. Sulfiredoxin translocation into mitochondria plays a crucial role in reducing hyperoxidized peroxiredoxin III. Journal of Biological Chemistry 2009, 284:8470-8477. http://www.ncbi.nlm.nih.gov/pubmed/19176523, 10.1074/jbc.M808981200.
4. Jönsson T.J., Tsang A.W., Lowther W.T., Furdui C.M. Identification of intact protein thiosulfinate intermediate in the reduction of cysteine sulfinic acid in peroxiredoxin by human sulfiredoxin. Journal of Biological Chemistry 2008, 283:22890-22894. http://www.ncbi.nlm.nih.gov/pubmed/18593714, 10.1074/jbc.C800124200.
5. Glauser D.A., Brun T., Gauthier B.R., Schlegel W. Transcriptional response of pancreatic beta cells to metabolic stimulation: large scale identification of immediate-early and secondary response genes. BMC Molecular Biology 2007, 8:54. http://www.ncbi.nlm.nih.gov/pubmed/17587450, 10.1186/1471-2199-8-54.
6. Papadia S., Soriano F.X., Léveillé F., Martel M.A., Dakin K.A., Hansen H.H., et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nature Neuroscience 2008, 11:476-487. http://www.ncbi.nlm.nih.gov/pubmed/18344994, 10.1038/nn2071.
7. Soriano F.X., Léveillé F., Papadia S., Higgins L.G., Varley J., Baxter P., et al. Induction of sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the neuroprotective Nrf2 activator 3H-1,2-dithiole-3-thione. Journal of Neurochemistry 2008, 107:533-543. http://www.ncbi.nlm.nih.gov/pubmed/18761713, 10.1111/j.1471-4159.2008.05648.x.
8. Wei Q., Jiang H., Matthews C.P., Colburn N.H. Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:19738-19743. http://www.ncbi.nlm.nih.gov/pubmed/19057013, 10.1073/pnas.0810676105.
9. Soriano F.X., Baxter P., Murray L.M., Sporn M.B., Gillingwater T.H., Hardingham G.E. Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Molecules and Cells 2009, 27:279-282. http://www.ncbi.nlm.nih.gov/pubmed/19326073, 10.1007/s10059-009-0050-y.
10. Bozonet S.M., Findlay V.J., Day A.M., Cameron J., Veal E.A., Morgan B.A. Oxidation of a eukaryotic 2-Cys peroxiredoxin is a molecular switch controlling the transcriptional response to increasing levels of hydrogen peroxide. Journal of Biological Chemistry 2005, 280:23319-23327. http://www.ncbi.nlm.nih.gov/pubmed/15824112, 10.1074/jbc.M502757200.
11. Findlay V.J., Tapiero H., Townsend D.M. Sulfiredoxin: a potential therapeutic agent?. Biomedicine and Pharmacotherapy 2005, 59:374-379. http://www.ncbi.nlm.nih.gov/pubmed/16102934, 10.1016/j.biopha.2005.07.003.
12. Findlay V.J., Townsend D.M., Morris T.E., Fraser J.P., He L., Tew K.D. A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Research 2006, 66:6800-6806. http://www.ncbi.nlm.nih.gov/pubmed/16818657, 10.1158/0008-5472.CAN-06-0484.
13. Harada N., Ito K., Hosoya T., Mimura J., Maruyama A., Noguchi N., et al. Nrf2 in bone marrow-derived cells positively contributes to the advanced stage of atherosclerotic plaque formation. Free Radical Biology and Medicine 2012, 53:2256-2262. http://www.ncbi.nlm.nih.gov/pubmed/23051009, 10.1016/j.freeradbiomed.2012.10.001.
14. Singh A., Ling G., Suhasini A.N., Zhang P., Yamamoto M., Navas-Acien A., et al. Nrf2-dependent sulfiredoxin-1 expression protects against cigarette smoke-induced oxidative stress in lungs. Free Radical Biology and Medicine 2009, 46:376-386. 10.1016/j.freeradbiomed.2008.10.026.
15. Merikallio H., Pääkkö P., Kinnula V.L., Harju T., Soini Y. Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Human Pathology 2012, 43:577-584. 10.1016/j.humpath.2011.05.024.
16. Soini Y., Eskelinen M., Juvonen P., Kärjä V., Haapasaari K.M., Saarela A. Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma. Pathology, Research and Practice 2014, 210:35-39. http://www.ncbi.nlm.nih.gov/pubmed/24189098, 10.1016/j.prp.2013.10.001.
17. Johnson J.L., Newby A.C. Macrophage heterogeneity in atherosclerotic plaques. Current Opinion in Lipidology 2009, 20:370-378. http://www.ncbi.nlm.nih.gov/pubmed/19741337, 10.1097/MOL.0b013e3283309848.
18. Freigang S., Ampenberger F., Spohn G., Heer S., Shamshiev A.T., Kisielow J., et al. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. European Journal of Immunology 2011, 41:2040-2051. http://www.ncbi.nlm.nih.gov/pubmed/21484785, 10.1002/eji.201041316.
19. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225. http://www.ncbi.nlm.nih.gov/pubmed/21124315, 10.1038/nature09663.
20. 2 in red blood cells. Antioxidants and Redox Signaling 2010, 12:1235-1246. http://www.ncbi.nlm.nih.gov/pubmed/20070187, 10.1089/ars.2009.2701.
21. Cabello C.M., Bair W.B., Lamore S.D., Ley S., Bause A.S., Azimian S., et al. The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth. Free Radical Biology and Medicine 2009, 46:220-231. 10.1016/j.freeradbiomed.2008.10.025.
22. Pozzesi N., Pierangeli S., Vacca C., Falchi L., Pettorossi V., Martelli M.P., et al. Maesopsin 4-O-β-D-glucoside, a natural compound isolated from the leaves of artocarpus tonkinensis , inhibits proliferation and up-regulates HMOX1, SRXN1 and BCAS3 in acute myeloid leukemia. Journal of Chemotherapy 2011, 23:150-157. 10.1179/joc.2011.23.3.150.
23. Koto K.S., Lescault P., Brard L., Kim K., Singh R.K., Bond J., et al. Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma. International Journal of Oncology 2011, 38:1329-1341. http://www.ncbi.nlm.nih.gov/pubmed/21399873, 10.3892/ijo.2011.971.
24. Han E.S., Muller F.L., Pérez V.I., Qi W., Liang H., Xi L., et al. The in vivo gene expression signature of oxidative stress. Physiological Genomics 2008, 34:112-126. http://www.ncbi.nlm.nih.gov/pubmed/18445702, 10.1152/physiolgenomics.00239.2007.
25. Bae S.H., Sung S.H., Cho E.J., Lee S.K., Lee H.E., Woo H.A., et al. Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver. Hepatology (Baltimore, Md.) 2011, 53:945-953. http://www.ncbi.nlm.nih.gov/pubmed/21319188, 10.1002/hep.24104.
26. Bae S.H., Sung S.H., Lee H.E., Kang H.T., Lee S.K., Oh S.Y., et al. Peroxiredoxin III and sulfiredoxin together protect mice from pyrazole-induced oxidative liver injury. Antioxidants and Redox Signaling 2012, 17:1351-1361. http://www.ncbi.nlm.nih.gov/pubmed/22490042, 10.1089/ars.2011.4334.
27. Wu K.C., Liu J.J., Klaassen C.D. Nrf2 activation prevents cadmium-induced acute liver injury. Toxicology and Applied Pharmacology 2012, 263:14-20. http://www.ncbi.nlm.nih.gov/pubmed/22677785, 10.1016/j.taap.2012.05.017.
28. McElwee M.K., Song M.O., Freedman J.H. Copper activation of NF-kappaB signaling in HepG2 cells. Journal of Molecular Biology 2009, 393:1013-1021. http://www.ncbi.nlm.nih.gov/pubmed/19747488, 10.1016/j.jmb.2009.08.077.
29. Hyeon S., Lee H., Yang Y., Jeong W. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation. Free Radical Biology and Medicine 2013, 65:789-799. http://www.ncbi.nlm.nih.gov/pubmed/23954472, 10.1016/j.freeradbiomed.2013.08.005.
30. Yazheng L., Kitts D.D. Activation of antioxidant response element (ARE)-dependent genes by roasted coffee extracts. Food and Function 2012, 3:950-954. http://www.ncbi.nlm.nih.gov/pubmed/22699814, 10.1039/c2fo30021d.
31. Al-Rejaie S.S., Aleisa A.M., Sayed-Ahmed M.M., Al-Shabanah O.A., Abuohashish H.M., Ahmed M.M., et al. Protective effect of rutin on the antioxidant genes expression in hypercholestrolemic male Westar rat. BMC Complementary and Alternative Medicine 2013, 13:136. http://www.ncbi.nlm.nih.gov/pubmed/23773725, 10.1186/1472-6882-13-136.
32. Park J.I., Jeon H.J., Jung N.K., Jang Y.J., Kim J.S., Seo Y.W. Periovulatory expression of hydrogen peroxide-induced sulfiredoxin and peroxiredoxin 2 in the rat ovary: gonadotropin regulation and potential modification. Endocrinology 2012, 153:5512-5521. http://www.ncbi.nlm.nih.gov/pubmed/22989627, 10.1210/en.2012-1414.
33. Shkolnik K., Tadmor A., Ben-Dor S., Nevo N., Galiani D., Dekel N. Reactive oxygen species are indispensable in ovulation. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:1462-1467. http://www.ncbi.nlm.nih.gov/pubmed/21220312, 10.1073/pnas.1017213108.
34. 2-dependent, reversible inactivation of peroxiredoxin III in mitochondria. Molecular Cell 2012, 46:584-594. 10.1016/j.molcel.2012.05.030.
35. Abbas K., Breton J., Planson A.G., Bouton C., Bignon J., Seguin C., et al. Nitric oxide activates an Nrf2/sulfiredoxin antioxidant pathway in macrophages. Free Radical Biology and Medicine 2011, 51:107-114. http://www.ncbi.nlm.nih.gov/pubmed/21466852, 10.1016/j.freeradbiomed.2011.03.039.
36. Diet A., Abbas K., Bouton C., Guillon B., Tomasello F., Fourquet S., et al. Regulation of peroxiredoxins by nitric oxide in immunostimulated macrophages. Journal of Biological Chemistry 2007, 282:36199-36205. 10.1074/jbc.M706420200.
37. Kim H., Jung Y., Shin B.S., Kim H., Song H., Bae S.H., et al. Redox regulation of lipopolysaccharide-mediated sulfiredoxin induction, which depends on both AP-1 and Nrf2. Journal of Biological Chemistry 2010, 285:34419-34428. http://www.ncbi.nlm.nih.gov/pubmed/20826812, 10.1074/jbc.M110.126839.
38. Ischiropoulos H., Zhu L., Beckman J.S. Peroxynitrite formation from macrophage-derived nitric oxide. Archives of Biochemistry and Biophysics 1992, 298:446-451. http://www.ncbi.nlm.nih.gov/pubmed/1329657, 10.1016/0003-9861(92)90433-W.
39. Bae S.H., Woo H.A., Sung S.H., Lee H.E., Lee S.K., Kil I.S. Induction of sulfiredoxin via an Nrf2-dependent pathway and hyperoxidation of peroxiredoxin III in the lungs of mice exposed to hyperoxia. Antioxidants and Redox Signaling 2009, 11:937-948. http://www.ncbi.nlm.nih.gov/pubmed/19086807, 10.1089/ars.2008.2325.
40. 2. Journal of Biological Chemistry 2012, 287:81-89. http://www.ncbi.nlm.nih.gov/pubmed/22086924, 10.1074/jbc.M111.316711.
41. Lei K., Townsend D.M., Tew K.D. Protein cysteine sulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response. Oncogene 2008, 27:4877-4887. http://www.ncbi.nlm.nih.gov/pubmed/18454177, 10.1038/onc.2008.132.
42. Planson A.G., Palais G., Abbas K., Gerard M., Couvelard L., Delaunay A., et al. Sulfiredoxin protects mice from lipopolysaccharide-induced endotoxic shock. Antioxidants and Redox Signaling 2011, 14:2071-2080. http://www.ncbi.nlm.nih.gov/pubmed/21083423, 10.1089/ars.2010.3552.
43. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140:871-882. http://www.ncbi.nlm.nih.gov/pubmed/20303877, 10.1016/j.cell.2010.02.029.
44. Wei Q., Jiang H., Baker A., Dodge L.K., Gerard M., Young M.R. Loss of sulfiredoxin renders mice resistant to azoxymethane/dextran sulfate sodium-induced colon carcinogenesis. Carcinogenesis 2013, 34:1403-1410. http://www.ncbi.nlm.nih.gov/pubmed/23393226, 10.1093/carcin/bgt059.
45. Wu L., Jiang H., Chawsheen H.A., Mishra M., Young M.R., Gerard M., et al. Tumor promoter-induced sulfiredoxin is required for mouse skin tumorigenesis. Carcinogenesis 2014, 35:1177-1184. http://www.ncbi.nlm.nih.gov/pubmed/24503444, 10.1093/carcin/bgu035.
46. Wei Q., Jiang H., Xiao Z., Baker A., Young M.R., Veenstra T.D., et al. Sulfiredoxin-peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:7004-7009. http://www.ncbi.nlm.nih.gov/pubmed/21487000, 10.1073/pnas.1013012108.
47. Bowers R.R., Manevich Y., Townsend D.M., Tew K.D. Sulfiredoxin redox-sensitive interaction with S100a4 and non-muscle myosin IIA regulates cancer cell motility. Biochemistry 2012, 51:7740-7754. http://www.ncbi.nlm.nih.gov/pubmed/22934964, 10.1021/bi301006w.
48. Kim Y.S., Lee H.L., Lee K.B., Park J.H., Chung W.Y., Lee K.S. Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. Korean Journal of Internal Medicine 2011, 26:304-313. http://www.ncbi.nlm.nih.gov/pubmed/22016591, 10.3904/kjim.2011.26.3.304.
49. Seliger B., Dressler S.P., Massa C., Recktenwald C.V., Altenberend F., Bukur J. Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells. Proteomics 2011, 11:2528-2541. http://www.ncbi.nlm.nih.gov/pubmed/21595034, 10.1002/pmic.201000486.